Corroborating this, RIPK3 deficiency or treatment with GSK’872, a specific inhibitor of RIPK3, markedly attenuates inflammatory cell influx along with IL-1α/β, IL-6, IL-18 secretion, and HMGB1 release, and tissue injury in an LPS-induced ALI model [97]. This evidence concerns the gene IL18 and acute respiratory distress syndrome.